/publications/issue/2005/2005-11/2005-11-4964

Fragmin (dalteparin sodium injection)

Author:

Eisai Inc (Teaneck, NJ) recently announced an in-license agreement with Pfizer Inc for exclusive US rights to promote Fragmin. The company will also assume responsibility for postmarketing studies and product distribution, as well as book all US sales. Fragmin is a clot-preventing agent, for subcutaneous injection only, in a class of drugs known as low-molecular-weight heparins. In the United States, Fragmin is indicated for prevention of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing hip replacement surgery, in at-risk patients undergoing abdominal surgery, or in at-risk acutely ill patients whose mobility is severely restricted. The product is also approved for prophylaxis of ischemic complications resulting from unstable angina and non-Q-wave myocardial infarction, when used with aspirin. For more information, visit www.fragmin.com.